glp-1 drugs microdosing Why Microdosing? A Closer Look at Reported Benefits Microdosing GLP-1s: Does It Work?

Grill HJ, Hayes MR

The firm plans to spend $3 billion in China over the coming decade to expand its supply chain and build local manufacturing capacity, including for GLP-1 medications

[DOI] [PMC free article] [PubMed] [Google Scholar] 34.Li H., Yao W., Liu Z., Xu A., Huang Y., Ma X.L., Irwin M.G., Xia Z

This bone loss exceeds what can be attributed solely to the substantial weight reduction associated with RYGB

Lau D (2024) In HFpEF with obesity, semaglutide improved health status and weight loss at 52 wk, regardless of initial health status

as initiated) analyses, initiation of a GLP-1 receptor agonist was associated with a reduced risk of several incident SUDs (fig 3, fig 4, and supplementary table S6), including disorders related to alcohol use (hazard ratio 0.82 (95% CI 0.78 to 0.85), NRD per 1000 people 5.57 (6.61 to 4.53)), cannabis use (0.86 (0.81 to 0.90), NRD 2.25 (3.00 to 1.50)), cocaine use (0.80 (0.72 to 0.88), NRD 0.97 (1.37 to 0.57)), nicotine use (0.80 (0.74 to 0.87), NRD 1.64 (2.19 to 1.09)), and opioids use (0.75 (0.67 to 0.85), NRD 0.86 (1.19 to 0.52)), and other SUDs (0.87 (0.81 to 0.94), NRD 1.12 (1.68 to 0.55))